However, two clinical trials indicated no immediate or long-term benefit for patients with moderate to severe COPD of systemic treatment with the anti-TNF-α monoclonal antibody Infliximab (Rennard et al., 2007, 2013). Here, TNF is linked to chronic obstructive pulmonary disease.